博瑞策生物技术（上海）有限公司获“A轮”融资，金额超亿人民币

Group 1 - The core point of the article is that Borui Biotechnology (Shanghai) Co., Ltd. has recently completed its Series A financing round, raising over 100 million RMB, with investors including Qianji Capital and Daotong Investment [1] - Borui Biotechnology was established in 2022 and is primarily engaged in research and experimental development, with a registered capital of 2.977362 million RMB [1] - The company has made one external investment and holds 15 trademark registrations and 10 patents, along with 11 administrative licenses [1] Group 2 - The legal representative of Borui Biotechnology is Liu Haiyang, and the company is located in Shanghai [1] - The shareholders of Borui Biotechnology include Shijiazhuang Hexin Zhongce Biotechnology Partnership, Baier Keta Biotechnology (Shanghai) Co., Ltd., Hainan Weichuang Biotechnology Partnership, Beijing Junlian Huikang Equity Investment Partnership, and Beijing Ocean Blue Biotechnology Co., Ltd. [1]